Browsing by Author "Jaiswal, Anil K."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    A prospective randomized comparison of simultaneous integrated boost with sequential boost intensity-modulated radiotherapy in locally advanced head and neck cancer
    (Wolters Kluwer Medknow Publications, 2022) Mani, Nilesh; Aggarwal, Sushil K.; Kumar, Ishan; Mandal, Abhijit; Jaiswal, Garima; Ranjan, Rakesh; Jaiswal, Anil K.; Gupta, Neha; Singh, Ankita; Mourya, Ankur; Aggarwal, Lalit M.; Choudhary, Sunil
    Purpose: A comparison of simultaneous integrated boost (SIB) with sequential boost (SEQ) using intensity-modulated radiotherapy along with concurrent cisplatin in locally advanced head and neck cancer (HNC) was made with regard to their survival outcomes and toxicity profile. Materials and Methods: A total of 34 patients were enrolled between October 2016 and March 2019. They were randomized into two arms, SIB and SEQB. All patients were treated with 6 MV photon beam on Linear Accelerator with weekly concurrent cisplatin at 35 mg/m 2. Overall survival (OS) and disease-free survival (DFS) were the primary end points and acute and late toxicities were the secondary end points. Results: The median follow-up period was 40.6 and 37.3 months for SIB and SEQB, respectively. At the end of 5 years, the median OS was 40.6 and 37.3 months (P = 0.947) and the median DFS was 35.1 and 37.3 months in the SIB and SEQB arms, respectively (P = 0.991).complete response at 3 months was 64.7% and 76.5% and partial response was 23.5% and 17.6%, whereas progressive disease was 11.8% and 5.9% in SIB and SEQB arms, respectively. Acute dermatitis, mucositis, dysphagia, and salivary gland toxicities were higher in the SIB arm compared to the SEQB arm. Conclusion: SIB and SEQ arms were comparable in terms of OS and DFS. However, the acute toxicities were higher in the SIB arm, although the difference was not significant, compared to the SEQB arm. � 2022 Wolters Kluwer Medknow Publications. All rights reserved.
  • Thumbnail Image
    Publication
    Percutaneous high?dose?rate interstitial brachytherapy for non?resectable, chemo resistant malignant lesion of lung and liver
    (Wolters Kluwer Medknow Publications, 2023) Yadawa, Nandlal; Shahi, Uday P.; Mandal, Abhijit; Verma, Ashish; Kumari, Kiran; Aggrawal, Lalit M.; Jaiswal, Isha; Mourya, Ankur; Jaiswal, Anil K.; Srivastava, Pammy
    Purpose: To explore the feasibility and efficacy of interstitial brachytherapy application for nonresectable and chemo?resistant malignant liver and lung lesions. Materials and Methods: Percutaneous high?dose?rate interstitial brachytherapy (HDR ISBT) was applied in nine lesions of seven middle?aged patients with advanced carcinoma (five patients with liver lesion and two patients with lung lesion). All patients were surgically ineligible. All patients had already received systemic chemotherapy. Under computed tomography (CT) guidance (for lung lesion) or ultrasonography (USG) guidance (for liver lesion), a single stainless steel brachytherapy needle was inserted percutaneously in patients with lesion size ?4 centimeter (cm) and multiple needles were inserted in patients of lesion size >4cm. A single dose of 15 Gy to 20 Gy with HDR ISBT was prescribed at the periphery of the lesion. The needles were removed just after treatment. Patients were kept under observation for 24 h after treatment. Results: The median size of the lesion was 6.5 cm. In all the cases of liver lesion, more than 75% shrinkage of tumor volume in follow?up at 6 mo was observed. It was more than 50% for lung lesion. None of the patients had developed significant complications as on the median follow up period of 15 mo (ranges 3�27 mo). Conclusions: Percutaneous CT?guided high?dose?rate interstitial brachytherapy is a minimally invasive, safe, and feasible treatment option with minimal complication for inoperable, chemo resistant, advanced cancers with encouraging treatment outcomes. � 2023 Journal of Cancer Research and Therapeutics.